SRScott R. Rajski

Scott R. Rajski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Scott R. Rajski has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of New Everninomicin Analogs from a Marine-Derived Micromonospora sp. by Metabolomics and Genomics Approaches

    by Tae Hyun Lee, Nathan J. Brittin, Imraan Alas, Christopher D. Roberts, Shaurya Chanana, Doug R. Braun, Spencer S. Ericksen, Song Guo, Scott R. Rajski, Tim S. Bugni

    During the course of genome mining initiatives, we identified a marine-derived Micromonospora, assigned here as strain WMMD956; the genome of WMMD956 appeared to contain a number of features associated with everninomicins, well-known antimicrobial orthosomycins. In addition, LCMS-based hierarchical clustering analysis and principal component analysis (hcapca) revealed that WMMD956 displayed an extreme degree of metabolomic and genomic novelty. Dereplication of high-resolution tandem mass spectrometry (HRMS/MS) and Global Natural Product Social molecular networking platform (GNPS) analysis of WMMD956 resulted in the identification of several analogs of the previously known everninomicin. Chemical structures were unambiguously confirmed by HR-ESI-MS, 1D and 2D NMR experiments, and the use of MS/MS data. The isolated metabolites, 1–3, were evaluated for their antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).


  • Open Access

    Evidence for Divergence of the Genus ‘Solwaraspora’ Within the Bacterial Family Micromonosporaceae

    by Hailee I. Porter, Imraan Alas, Nyssa K. Krull, Doug R. Braun, Scott R. Rajski, Brian T. Murphy, Tim S. Bugni

    The purpose of this study was to investigate the taxonomic and phylogenomic placement of the proposed genus ‘Solwaraspora’ within the context of other marine genera using a dual-omics approach. Initially, we isolated bacteria from marine tunicates, squirts, and sponges, which were morphologically similar to an emerging genus (identified as ‘Micromonospora_E’ by the GTDB-tk2 database using whole genome sequence data) by colony shape, size, and clustering pattern, but only found five strains in our dataset belonging to this distinction. Due to the minimally explored nature of this genus, we sought to identify more bacterial strains with similar morphology to Micromonospora‘Micromonospora_E’ by whole genome sequencing (WGS). Within our collection, we noted 35 strains that met this criterion and extracted genomic information to perform WGS on these strains. With this information, we studied taxonomic and phylogenomic relationships among these organisms. Using the data gathered from WGS, we were able to identify an additional five strains labeled by the GTDB-tk2 database as Micromonospora‘Micromonospora_E’, as well as construct phylogenomic trees to examine the evolutionary relationships between these strains. ANI values were calculated between strains from our dataset and type strains of Micromonospora and Plantactinospora as well as against an outgroup Streptomyces strain. No type strains are available for ‘Solwaraspora’. Using MALDI-TOF MS, we positively identified ‘Solwaraspora’, which was supported by the phylogenomic tree showing Micromonospora’Micromonospora_E’ (‘Solwaraspora’) in a distinct clade from Plantactinospora and Micromonospora. Additionally, we discovered gene cluster families (GCFs) in alignment with genera, as well as a large representation of biosynthetic gene clusters (BGCs) coming from the ‘Solwaraspora’ strains. These findings suggest significant potential to discover novel chemistry from ‘Solwaraspora’, adding to the importance of investigating this new genus of bacteria.

  • Open Access

    Isolation, Structure Elucidation and Biological Evaluation of Lomaiviticins F–H, Dimeric Benzofluorene Glycosides from Marine-Derived Micromonospora sp. Bacterium

    by Fan Zhang, Wenhui Wang, Doug R. Braun, Gene E. Ananiev, Weiting Liao, Mary Kay Harper, Scott R. Rajski, Tim S. Bugni

    The discovery of new natural products remains a cornerstone of therapeutic innovation, and effective analytical tools for rapid dereplication can significantly accelerate this process. Using Isotopic Fine Structure (IFS) mass spectrometry, we rapidly identified three new dimeric benzofluorene glycosides, lomaiviticins F–H (1–3), from a marine-derived Micromonospora sp. bacterium. These compounds were isolated and structurally elucidated through advanced spectroscopic techniques, including FT-ICR-MS and NMR. Lomaiviticins F–H exhibit unique structural features, notably the 4-O-methyl-l-angolosamine moieties, which differentiate them from previously known lomaiviticins A–E. The discovery of these compounds highlights distinct biosynthetic linkages within the lomaiviticin family, particularly the C2–C2′ conjoining bonds characteristic of the dimers. Compounds 1–3 were evaluated for in vitro cytotoxicity against a panel of human cancer cell lines; the resulting IC50 values confirmed that the dimeric diazofluorenes of lomaiviticins A and B are critical for anticancer activity. These findings emphasize the utility of IFS in expediting natural product discovery while providing valuable insights into structural and functional characterizations of bioactive compounds.


  • Open Access

    Dereplication of Natural Product Antifungals via Liquid Chromatography–Tandem Mass Spectrometry and Chemical Genomics

    by Nathaniel J. Brittin, David J. Aceti, Doug R. Braun, Josephine M. Anderson, Spencer S. Ericksen, Scott R. Rajski, Cameron R. Currie, David R. Andes, Tim S. Bugni

    Recently expanded reports of multidrug-resistant fungal infections underscore the need to develop new and more efficient methods for antifungal drug discovery. A ubiquitous problem in natural product drug discovery campaigns is the rediscovery of known compounds or their relatives; accordingly, we have integrated Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) for structural dereplication and Yeast Chemical Genomics for bioprocess evaluation into a screening platform to identify such compounds early in the screening process. We identified 450 fractions inhibiting Candida albicans and the resistant strains of C. auris and C. glabrata among more than 40,000 natural product fractions. LC-MS/MS and chemical genomics were then used to identify those with known chemistry and mechanisms of action. The parallel deployment of these orthogonal methods improved the detection of unwanted compound classes over the methods applied individually.


  • Open Access

    Micromonosporaceae biosynthetic gene cluster diversity highlights the need for broad-spectrum investigations

    by Imraan Alas, Doug R. Braun, Spencer S. Ericksen, Rauf Salamzade, Lindsay Kalan, Scott R. Rajski, Tim S. Bugni

    Investigations of the bacterial family Micromonosporaceae have enabled the development of secondary metabolites critical to human health. Historical investigation of bacterial families for natural product discovery has focused on terrestrial strains, where time-consuming isolation processes often lead to the rediscovery of known compounds. To investigate the secondary metabolite potential of marine-derived Micromonosporaceae , 38 strains were sequenced, assembled and analysed using antiSMASH and BiG-SLiCE. BiG-SLiCE contains a near-comprehensive dataset of approximately 1.2 million publicly available biosynthetic gene clusters from primarily terrestrial strains. Our marine-derived Micromonosporaceae were directly compared to BiG-SLiCE’s preprocessed database using BiG-SLiCE’s query mode; genetic diversity within our strains was uncovered using BiG-SCAPE and metric multidimensional scaling analysis. Our analysis of marine-derived Micromonosporaceae emphasizes the clear need for broader genomic investigations of marine strains to fully realize their potential as sources of new natural products.


  • Open Access

    Bacillimidazoles A−F, Imidazolium-Containing Compounds Isolated from a Marine Bacillus

    by Jia-Xuan Yan, Qihao Wu, Eric J. N. Helfrich, Marc G. Chevrette, Doug R. Braun, Heino Heyman, Gene E. Ananiev, Scott R. Rajski, Cameron R. Currie, Jon Clardy, et al.

    Chemical investigations of a marine sponge-associated Bacillus revealed six new imidazolium-containing compounds, bacillimidazoles A–F (1–6). Previous reports of related imidazolium-containing natural products are rare. Initially unveiled by timsTOF (trapped ion mobility spectrometry) MS data, extensive HRMS and 1D and 2D NMR analyses enabled the structural elucidation of 1–6. In addition, a plausible biosynthetic pathway to bacillimidazoles is proposed based on isotopic labeling experiments and invokes the highly reactive glycolytic adduct 2,3-butanedione. Combined, the results of structure elucidation efforts, isotopic labeling studies and bioinformatics suggest that 1–6 result from a fascinating intersection of primary and secondary metabolic pathways in Bacillus sp. WMMC1349. Antimicrobial assays revealed that, of 1–6, only compound six displayed discernible antibacterial activity, despite the close structural similarities shared by all six natural products.


  • Turbinmicin inhibits Candida biofilm growth by disrupting fungal vesicle–mediated trafficking

    by Miao Zhao, Fan Zhang, Robert Zarnowski, Kenneth Barns, Ryley Jones, Jen Fossen, Hiram Sanchez, Scott R. Rajski, Anjon Audhya, Tim S. Bugni, et al.

    The emergence of drug-resistant fungi has prompted an urgent threat alert from the US Centers for Disease Control (CDC). Biofilm assembly by these pathogens further impairs effective therapy. We recently identified an antifungal, turbinmicin, that inhibits the fungal vesicle–mediated trafficking pathway and demonstrates broad-spectrum activity against planktonically growing fungi. During biofilm growth, vesicles with unique features play a critical role in the delivery of biofilm extracellular matrix components. As these components are largely responsible for the drug resistance associated with biofilm growth, we explored the utility of turbinmicin in the biofilm setting. We found that turbinmicin disrupted extracellular vesicle (EV) delivery during biofilm growth and that this impaired the subsequent assembly of the biofilm matrix. We demonstrated that elimination of the extracellular matrix rendered the drug-resistant biofilm communities susceptible to fungal killing by turbinmicin. Furthermore, the addition of turbinmicin to otherwise ineffective antifungal therapy potentiated the activity of these drugs. The underlying role of vesicles explains this dramatic activity and was supported by phenotype reversal with the addition of exogenous biofilm EVs. This striking capacity to cripple biofilm assembly mechanisms reveals a new approach to eradicating biofilms and sheds light on turbinmicin as a promising anti-biofilm drug.


  • A marine microbiome antifungal targets urgent-threat drug-resistant fungi

    by Fan Zhang, Miao Zhao, Doug R. Braun, Spencer S. Ericksen, Jeff S. Piotrowski, Justin Nelson, Jian Peng, Gene E. Ananiev, Shaurya Chanana, Kenneth Barns, et al.

    Prospecting for antifungal molecules: Marine bacteria produce a plethora of natural products that often have unusual chemical structures and corresponding reactivity, which sometimes translate into a valuable biological function. Zhang et al. used a metabolomic screen to zero in on microbial strains from the microbiome of a sea squirt that produces a high diversity of chemical structures. They then screened these molecules for inhibition of fungi (see the Perspective by Cowen). A polycyclic molecule dubbed turbinmicin possessed potent antifungal activity against the multidrug-resistant fungal pathogens Candida auris and Aspergillus fumigatus . Preliminary mechanism-of-action and mouse toxicity studies suggest that this molecule works though a fungus-specific pathway and is well tolerated at therapeutic doses. Science , this issue p. 974 ; see also p. 906


  • Open Access

    Draft Genome Sequence of Pseudenhygromyxa sp. Strain WMMC2535, a Marine Ascidian-Associated Bacterium

    by Shaurya Chanana, Doug R. Braun, Scott R. Rajski, Tim S. Bugni

    Pseudenhygromyxa WMMC2535, a representative of the myxobacteria (family Nannocystaceae ), was isolated from a ragged sea hare in the Florida Keys, and its genome was sequenced using PacBio technology. The WMMC2535 genome sequence is the first of this genus and validates the notion that myxobacteria represent outstanding sources of structurally diverse natural products.


  • Open Access

    hcapca: Automated Hierarchical Clustering and Principal Component Analysis of Large Metabolomic Datasets in R

    by Shaurya Chanana, Chris S. Thomas, Fan Zhang, Scott R. Rajski, Tim S. Bugni

    Microbial natural product discovery programs face two main challenges today: rapidly prioritizing strains for discovering new molecules and avoiding the rediscovery of already known molecules. Typically, these problems have been tackled using biological assays to identify promising strains and techniques that model variance in a dataset such as PCA to highlight novel chemistry. While these tools have shown successful outcomes in the past, datasets are becoming much larger and require a new approach. Since PCA models are dependent on the members of the group being modeled, large datasets with many members make it difficult to accurately model the variance in the data. Our tool, hcapca, first groups strains based on the similarity of their chemical composition, and then applies PCA to the smaller sub-groups yielding more robust PCA models. This allows for scalable chemical comparisons among hundreds of strains with thousands of molecular features. As a proof of concept, we applied our open-source tool to a dataset with 1046 LCMS profiles of marine invertebrate associated bacteria and discovered three new analogs of an established anticancer agent from one promising strain.